Feng Shao, Xiao Han, Nanxin Li, Weiwen Wang. Eur J Pharmacol 2010
Times Cited: 7
Times Cited: 7
Times Cited
Times Co-cited
Similarity
Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.
Sandeep T Patil, Lu Zhang, Ferenc Martenyi, Stephen L Lowe, Kimberley A Jackson, Boris V Andreev, Alla S Avedisova, Leonid M Bardenstein, Issak Y Gurovich, Margarita A Morozova,[...]. Nat Med 2007
Sandeep T Patil, Lu Zhang, Ferenc Martenyi, Stephen L Lowe, Kimberley A Jackson, Boris V Andreev, Alla S Avedisova, Leonid M Bardenstein, Issak Y Gurovich, Margarita A Morozova,[...]. Nat Med 2007
57
Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?
Gerard J Marek, Berthold Behl, Anton Y Bespalov, Gerhard Gross, Younglim Lee, Hans Schoemaker. Mol Pharmacol 2010
Gerard J Marek, Berthold Behl, Anton Y Bespalov, Gerhard Gross, Younglim Lee, Hans Schoemaker. Mol Pharmacol 2010
42
NMDA receptor hypofunction model of schizophrenia.
J W Olney, J W Newcomer, N B Farber. J Psychiatr Res 1999
J W Olney, J W Newcomer, N B Farber. J Psychiatr Res 1999
42
The difference in effect of mGlu2/3 and mGlu5 receptor agonists on cognitive impairment induced by MK-801.
Karel Vales, Jan Svoboda, Kristina Benkovicova, Vera Bubenikova-Valesova, Ales Stuchlik. Eur J Pharmacol 2010
Karel Vales, Jan Svoboda, Kristina Benkovicova, Vera Bubenikova-Valesova, Ales Stuchlik. Eur J Pharmacol 2010
42
Therapeutic effects of metabotropic glutamate receptor 5 positive allosteric modulator CDPPB on phencyclidine-induced cognitive deficits in mice.
Mao Horio, Yuko Fujita, Kenji Hashimoto. Fundam Clin Pharmacol 2013
Mao Horio, Yuko Fujita, Kenji Hashimoto. Fundam Clin Pharmacol 2013
28
Dopamine is not required for the hyperlocomotor response to NMDA receptor antagonists.
Elena H Chartoff, Carrie L Heusner, Richard D Palmiter. Neuropsychopharmacology 2005
Elena H Chartoff, Carrie L Heusner, Richard D Palmiter. Neuropsychopharmacology 2005
28
Enhancement of social novelty discrimination by positive allosteric modulators at metabotropic glutamate 5 receptors: adolescent administration prevents adult-onset deficits induced by neonatal treatment with phencyclidine.
Nicholas E Clifton, Nadège Morisot, Sylvie Girardon, Mark J Millan, Florence Loiseau. Psychopharmacology (Berl) 2013
Nicholas E Clifton, Nadège Morisot, Sylvie Girardon, Mark J Millan, Florence Loiseau. Psychopharmacology (Berl) 2013
28
The mGluR5 antagonist MPEP, but not the mGluR2/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity.
S A Henry, V Lehmann-Masten, F Gasparini, M A Geyer, A Markou. Neuropharmacology 2002
S A Henry, V Lehmann-Masten, F Gasparini, M A Geyer, A Markou. Neuropharmacology 2002
28
Interaction of N-methyl-D-aspartate and group 5 metabotropic glutamate receptors on behavioral flexibility using a novel operant set-shift paradigm.
Justin M Darrah, Mark R Stefani, Bita Moghaddam. Behav Pharmacol 2008
Justin M Darrah, Mark R Stefani, Bita Moghaddam. Behav Pharmacol 2008
28
Emerging roles for novel antipsychotic medications in the treatment of schizophrenia.
C Andersson, M Chakos, R Mailman, J Lieberman. Psychiatr Clin North Am 1998
C Andersson, M Chakos, R Mailman, J Lieberman. Psychiatr Clin North Am 1998
28
A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models.
Gene G Kinney, Julie A O'Brien, Wei Lemaire, Maryann Burno, Denise J Bickel, Michelle K Clements, Tsing-Bau Chen, David D Wisnoski, Craig W Lindsley, Philip R Tiller,[...]. J Pharmacol Exp Ther 2005
Gene G Kinney, Julie A O'Brien, Wei Lemaire, Maryann Burno, Denise J Bickel, Michelle K Clements, Tsing-Bau Chen, David D Wisnoski, Craig W Lindsley, Philip R Tiller,[...]. J Pharmacol Exp Ther 2005
28
Comparison of the mGlu(5) receptor positive allosteric modulator ADX47273 and the mGlu(2/3) receptor agonist LY354740 in tests for antipsychotic-like activity.
Chantal Schlumberger, Małgorzata Pietraszek, Andreas Gravius, Kai-Uwe Klein, Sergio Greco, Lorenzo Morè, Wojciech Danysz. Eur J Pharmacol 2009
Chantal Schlumberger, Małgorzata Pietraszek, Andreas Gravius, Kai-Uwe Klein, Sergio Greco, Lorenzo Morè, Wojciech Danysz. Eur J Pharmacol 2009
28
Recent advances in the phencyclidine model of schizophrenia.
D C Javitt, S R Zukin. Am J Psychiatry 1991
D C Javitt, S R Zukin. Am J Psychiatry 1991
28
Homer 1a gene expression modulation by antipsychotic drugs: involvement of the glutamate metabotropic system and effects of D-cycloserine.
Daniela Polese, Antonella Amato de Serpis, Alberto Ambesi-Impiombato, Giovanni Muscettola, Andrea de Bartolomeis. Neuropsychopharmacology 2002
Daniela Polese, Antonella Amato de Serpis, Alberto Ambesi-Impiombato, Giovanni Muscettola, Andrea de Bartolomeis. Neuropsychopharmacology 2002
28
Functional interactions between presynaptic NMDA receptors and metabotropic glutamate receptors co-expressed on rat and human noradrenergic terminals.
E Luccini, V Musante, E Neri, M Brambilla Bas, P Severi, M Raiteri, A Pittaluga. Br J Pharmacol 2007
E Luccini, V Musante, E Neri, M Brambilla Bas, P Severi, M Raiteri, A Pittaluga. Br J Pharmacol 2007
28
The mGlu₅ positive allosteric modulator LSN2463359 differentially modulates motor, instrumental and cognitive effects of NMDA receptor antagonists in the rat.
Francois Gastambide, Gary Gilmour, Trevor W Robbins, Mark D Tricklebank. Neuropharmacology 2013
Francois Gastambide, Gary Gilmour, Trevor W Robbins, Mark D Tricklebank. Neuropharmacology 2013
28
Dopamine hypothesis of schizophrenia: making sense of it all.
Mitsuru Toda, Anissa Abi-Dargham. Curr Psychiatry Rep 2007
Mitsuru Toda, Anissa Abi-Dargham. Curr Psychiatry Rep 2007
28
Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice.
C Chiamulera, M P Epping-Jordan, A Zocchi, C Marcon, C Cottiny, S Tacconi, M Corsi, F Orzi, F Conquet. Nat Neurosci 2001
C Chiamulera, M P Epping-Jordan, A Zocchi, C Marcon, C Cottiny, S Tacconi, M Corsi, F Orzi, F Conquet. Nat Neurosci 2001
28
MK-801 produces a deficit in sucrose preference that is reversed by clozapine, D-serine, and the metabotropic glutamate 5 receptor positive allosteric modulator CDPPB: relevance to negative symptoms associated with schizophrenia?
Joshua D Vardigan, Sarah L Huszar, Caitlyn H McNaughton, Peter H Hutson, Jason M Uslaner. Pharmacol Biochem Behav 2010
Joshua D Vardigan, Sarah L Huszar, Caitlyn H McNaughton, Peter H Hutson, Jason M Uslaner. Pharmacol Biochem Behav 2010
28
mGluR5, but not mGluR1, antagonist modifies MK-801-induced locomotor activity and deficit of prepulse inhibition.
M Pietraszek, A Gravius, D Schäfer, T Weil, D Trifanova, W Danysz. Neuropharmacology 2005
M Pietraszek, A Gravius, D Schäfer, T Weil, D Trifanova, W Danysz. Neuropharmacology 2005
28
Selective remediation of reversal learning deficits in the neurodevelopmental MAM model of schizophrenia by a novel mGlu5 positive allosteric modulator.
Francois Gastambide, Marie-Caroline Cotel, Gary Gilmour, Michael J O'Neill, Trevor W Robbins, Mark D Tricklebank. Neuropsychopharmacology 2012
Francois Gastambide, Marie-Caroline Cotel, Gary Gilmour, Michael J O'Neill, Trevor W Robbins, Mark D Tricklebank. Neuropsychopharmacology 2012
28
Metabotropic glutamate subtype 5 receptors modulate fear-conditioning induced enhancement of prepulse inhibition in rats.
Dan Zou, Juan Huang, Xihong Wu, Liang Li. Neuropharmacology 2007
Dan Zou, Juan Huang, Xihong Wu, Liang Li. Neuropharmacology 2007
28
Functional Interaction Between NMDA and mGlu5 Receptors: Effects on Working Memory, Instrumental Learning, Motor Behaviors, and Dopamine Release.
Houman Homayoun, Mark R Stefani, Barbara W Adams, Gilles D Tamagan, Bita Moghaddam. Neuropsychopharmacology 2004
Houman Homayoun, Mark R Stefani, Barbara W Adams, Gilles D Tamagan, Bita Moghaddam. Neuropsychopharmacology 2004
28
Comparing protein abundance and mRNA expression levels on a genomic scale.
Dov Greenbaum, Christopher Colangelo, Kenneth Williams, Mark Gerstein. Genome Biol 2003
Dov Greenbaum, Christopher Colangelo, Kenneth Williams, Mark Gerstein. Genome Biol 2003
28
Catching up on schizophrenia: natural history and neurobiology.
D A Lewis, J A Lieberman. Neuron 2000
D A Lewis, J A Lieberman. Neuron 2000
28
NMDA-induced phosphorylation and regulation of mGluR5.
Sudar Alagarsamy, Susan T Rouse, Candace Junge, G W Hubert, David Gutman, Yoland Smith, P Jeffrey Conn. Pharmacol Biochem Behav 2002
Sudar Alagarsamy, Susan T Rouse, Candace Junge, G W Hubert, David Gutman, Yoland Smith, P Jeffrey Conn. Pharmacol Biochem Behav 2002
28
Effects of a positive allosteric modulator of mGluR5 ADX47273 on conditioned avoidance response and PCP-induced hyperlocomotion in the rat as models for schizophrenia.
Chantal Schlumberger, Małgorzata Pietraszek, Andreas Gravius, Wojciech Danysz. Pharmacol Biochem Behav 2010
Chantal Schlumberger, Małgorzata Pietraszek, Andreas Gravius, Wojciech Danysz. Pharmacol Biochem Behav 2010
28
In vitro characterisation of the novel positive allosteric modulators of the mGlu₅ receptor, LSN2463359 and LSN2814617, and their effects on sleep architecture and operant responding in the rat.
Gary Gilmour, Lisa M Broad, Keith A Wafford, Thomas Britton, Ellen M Colvin, Adam Fivush, Francois Gastambide, Brian Getman, Beverly A Heinz, Andrew P McCarthy,[...]. Neuropharmacology 2013
Gary Gilmour, Lisa M Broad, Keith A Wafford, Thomas Britton, Ellen M Colvin, Adam Fivush, Francois Gastambide, Brian Getman, Beverly A Heinz, Andrew P McCarthy,[...]. Neuropharmacology 2013
28
Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: association with N-methyl-D-aspartic acid receptor up-regulation.
Laura Gray, Maarten van den Buuse, Elizabeth Scarr, Brian Dean, Anthony J Hannan. Int J Neuropsychopharmacol 2009
Laura Gray, Maarten van den Buuse, Elizabeth Scarr, Brian Dean, Anthony J Hannan. Int J Neuropsychopharmacol 2009
28
Behavioural pharmacology: 40+ years of progress, with a focus on glutamate receptors and cognition.
Trevor W Robbins, Emily R Murphy. Trends Pharmacol Sci 2006
Trevor W Robbins, Emily R Murphy. Trends Pharmacol Sci 2006
28
Glutamatergic mechanisms in schizophrenia.
Guochuan Tsai, Joseph T Coyle. Annu Rev Pharmacol Toxicol 2002
Guochuan Tsai, Joseph T Coyle. Annu Rev Pharmacol Toxicol 2002
28
Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP.
Y M Lu, Z Jia, C Janus, J T Henderson, R Gerlai, J M Wojtowicz, J C Roder. J Neurosci 1997
Y M Lu, Z Jia, C Janus, J T Henderson, R Gerlai, J M Wojtowicz, J C Roder. J Neurosci 1997
28
Activation of type 5 metabotropic glutamate receptors attenuates deficits in cognitive flexibility induced by NMDA receptor blockade.
Mark R Stefani, Bita Moghaddam. Eur J Pharmacol 2010
Mark R Stefani, Bita Moghaddam. Eur J Pharmacol 2010
28
Addressing side effects from antipsychotic treatment in schizophrenia.
John M Kane. J Clin Psychiatry 2011
John M Kane. J Clin Psychiatry 2011
28
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action.
F X Vollenweider, M F Vollenweider-Scherpenhuyzen, A Bäbler, H Vogel, D Hell. Neuroreport 1998
F X Vollenweider, M F Vollenweider-Scherpenhuyzen, A Bäbler, H Vogel, D Hell. Neuroreport 1998
28
The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment.
Ina Weiner. Psychopharmacology (Berl) 2003
Ina Weiner. Psychopharmacology (Berl) 2003
28
Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values.
H Y Meltzer, S Matsubara, J C Lee. J Pharmacol Exp Ther 1989
H Y Meltzer, S Matsubara, J C Lee. J Pharmacol Exp Ther 1989
28
Effects of microinjections of apomorphine and haloperidol into the inferior colliculus on the latent inhibition of the conditioned emotional response.
Liana L Melo, Ellen C H M Pereira, Cássia H Pagini, Norberto C Coimbra, Marcus L Brandão, Elenice A M Ferrari. Exp Neurol 2009
Liana L Melo, Ellen C H M Pereira, Cássia H Pagini, Norberto C Coimbra, Marcus L Brandão, Elenice A M Ferrari. Exp Neurol 2009
33
The M₁/M₄ preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia.
Segev Barak, Ina Weiner. Int J Neuropsychopharmacol 2011
Segev Barak, Ina Weiner. Int J Neuropsychopharmacol 2011
28
Glycine reuptake inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia.
Daniela Alberati, Jean-Luc Moreau, Judith Lengyel, Nicole Hauser, Roland Mory, Edilio Borroni, Emmanuel Pinard, Frederic Knoflach, Götz Schlotterbeck, Dominik Hainzl,[...]. Neuropharmacology 2012
Daniela Alberati, Jean-Luc Moreau, Judith Lengyel, Nicole Hauser, Roland Mory, Edilio Borroni, Emmanuel Pinard, Frederic Knoflach, Götz Schlotterbeck, Dominik Hainzl,[...]. Neuropharmacology 2012
28
Animal behavior models of the mechanisms underlying antipsychotic atypicality.
Mark A Geyer, Bart Ellenbroek. Prog Neuropsychopharmacol Biol Psychiatry 2003
Mark A Geyer, Bart Ellenbroek. Prog Neuropsychopharmacol Biol Psychiatry 2003
28
Influence of social isolation in the rat on serotonergic function and memory--relevance to models of schizophrenia and the role of 5-HT₆ receptors.
Charles A Marsden, Madeleine V King, Kevin C F Fone. Neuropharmacology 2011
Charles A Marsden, Madeleine V King, Kevin C F Fone. Neuropharmacology 2011
28
The dopamine hypothesis of schizophrenia: version III--the final common pathway.
Oliver D Howes, Shitij Kapur. Schizophr Bull 2009
Oliver D Howes, Shitij Kapur. Schizophr Bull 2009
28
Neural mechanisms of addiction: the role of reward-related learning and memory.
Steven E Hyman, Robert C Malenka, Eric J Nestler. Annu Rev Neurosci 2006
Steven E Hyman, Robert C Malenka, Eric J Nestler. Annu Rev Neurosci 2006
28
GABAergic interneuron origin of schizophrenia pathophysiology.
Kazu Nakazawa, Veronika Zsiros, Zhihong Jiang, Kazuhito Nakao, Stefan Kolata, Shuqin Zhang, Juan E Belforte. Neuropharmacology 2012
Kazu Nakazawa, Veronika Zsiros, Zhihong Jiang, Kazuhito Nakao, Stefan Kolata, Shuqin Zhang, Juan E Belforte. Neuropharmacology 2012
14
The behavioral profile of the potent and selective mGlu5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) in rodent models of anxiety.
Chris S Busse, Jesse Brodkin, David Tattersall, Jeffery J Anderson, Noelle Warren, Lida Tehrani, Linda J Bristow, Mark A Varney, Nicholas D P Cosford. Neuropsychopharmacology 2004
Chris S Busse, Jesse Brodkin, David Tattersall, Jeffery J Anderson, Noelle Warren, Lida Tehrani, Linda J Bristow, Mark A Varney, Nicholas D P Cosford. Neuropsychopharmacology 2004
14
The genomic organisation of the metabotropic glutamate receptor subtype 5 gene, and its association with schizophrenia.
R S Devon, S Anderson, P W Teague, W J Muir, V Murray, A J Pelosi, D H Blackwood, D J Porteous. Mol Psychiatry 2001
R S Devon, S Anderson, P W Teague, W J Muir, V Murray, A J Pelosi, D H Blackwood, D J Porteous. Mol Psychiatry 2001
14
Dose-dependent effect of CDPPB, the mGluR5 positive allosteric modulator, on recognition memory is associated with GluR1 and CREB phosphorylation in the prefrontal cortex and hippocampus.
Jason M Uslaner, Sophie Parmentier-Batteur, Rosemarie B Flick, Nathaniel O Surles, June S H Lam, Caitlyn H McNaughton, Marlene A Jacobson, Pete H Hutson. Neuropharmacology 2009
Jason M Uslaner, Sophie Parmentier-Batteur, Rosemarie B Flick, Nathaniel O Surles, June S H Lam, Caitlyn H McNaughton, Marlene A Jacobson, Pete H Hutson. Neuropharmacology 2009
14
The antianxiety-like effects of antagonists of group I and agonists of group II and III metabotropic glutamate receptors after intrahippocampal administration.
E Tatarczyńska, A Kłodzińska, B Kroczka, E Chojnacka-Wójcik, A Pilc. Psychopharmacology (Berl) 2001
E Tatarczyńska, A Kłodzińska, B Kroczka, E Chojnacka-Wójcik, A Pilc. Psychopharmacology (Berl) 2001
14
Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.